Story perspectives

Trump's Tariffs Spark US Pharma Investment, IP Uncertainty Looms

9/13/2025

34 2

Summary

Story summary

President Trump’s tariff policies are driving pharmaceutical companies to invest billions in US manufacturing, while their intellectual property (IP) may remain overseas.
Firms like Johnson & Johnson and AstraZeneca have announced major investments, but the status of their IP is uncertain.
Experts warn that relocating IP to the US could incur higher taxes, deterring such moves.
Trump seeks to pressure drugmakers to increase prices abroad to reduce them domestically, though experts doubt his enforcement capability.
The "Most Favoured Nation" pricing initiative faced legal challenges and was rescinded by the Biden administration, leading companies to retain existing IP abroad but potentially place new IP in the US.

1 of 1

Story summary

President Trump’s tariff policies are driving pharmaceutical companies to invest billions in US manufacturing, while their intellectual property (IP) may remain overseas.
Firms like Johnson & Johnson and AstraZeneca have announced major investments, but the status of their IP is uncertain.
Experts warn that relocating IP to the US could incur higher taxes, deterring such moves.
Trump seeks to pressure drugmakers to increase prices abroad to reduce them domestically, though experts doubt his enforcement capability.
The "Most Favoured Nation" pricing initiative faced legal challenges and was rescinded by the Biden administration, leading companies to retain existing IP abroad but potentially place new IP in the US.